MedPath

四川益生智同医药生物科技发展有限公司

Ownership
-
Established
2022-04-15
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

8

NMPA:8

Drug Approvals

Sitagliptin Phosphate Tablets

Product Name
磷酸西格列汀片
Approval Number
国药准字H20253976
Approval Date
Apr 22, 2025
NMPA

Fudosteine oral solution

Product Name
福多司坦口服溶液
Approval Number
国药准字H20253709
Approval Date
Mar 25, 2025
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20253497
Approval Date
Mar 4, 2025
NMPA

Famotidine Injection

Product Name
法莫替丁注射液
Approval Number
国药准字H20253496
Approval Date
Mar 4, 2025
NMPA

Aripiprazole Oral Solution

Product Name
阿立哌唑口服溶液
Approval Number
国药准字H20244236
Approval Date
Jun 28, 2024
NMPA

Hydrotalcite Suspension

Product Name
铝碳酸镁混悬液
Approval Number
国药准字H20243135
Approval Date
Feb 6, 2024
NMPA

Doxofylline Injection

Product Name
多索茶碱注射液
Approval Number
国药准字H20223576
Approval Date
Aug 10, 2022
NMPA

Doxofylline Injection

Product Name
多索茶碱注射液
Approval Number
国药准字H20213992
Approval Date
Dec 31, 2021
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.